Tonix Pharmaceuticals Announces Potential Positive Impact of the U.S. National Academies (NASEM) New Definition of Long COVID on the Size of the Fibromyalgia Market for Tonmya™
July 31, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Fibromyalgia is a “diagnosable condition” in people suffering from Long COVID according to NASEM1 Diagnosing fibromyalgia in Long COVID patients is expected to expand the potential...
Tonix Pharmaceuticals Announces Poster Presentation at the IASP 2024 World Congress on Pain
July 30, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Presentation to highlight statistically significant Phase 3 results of Tonmya™ for the management of fibromyalgia, including improvement in pain and sleep quality Tonix granted FDA Fast Track...
Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia
July 25, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Fast Track is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need Fast Track designation for Tonmya recognizes fibromyalgia as a...
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
July 10, 2024 16:30 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced the...
Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering
July 09, 2024 09:15 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced it has...
Tonix Pharmaceuticals Announces Proposed Public Offering
July 08, 2024 17:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced that it...
Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of Fibromyalgia
July 08, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia Approximately 10 million adults in the U.S. are affected by fibromyalgia, predominantly...
Tonix Pharmaceuticals Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program
July 01, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., July 01, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a...
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
June 28, 2024 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 28, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced the...
Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering
June 27, 2024 08:36 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced it has...